2018
DOI: 10.1002/ijc.31843
|View full text |Cite
|
Sign up to set email alerts
|

Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer

Abstract: Prostate cancer can be controlled by androgen-hormone treatment until the cancer becomes refractory. It is believed that hormone sensitivity is largely dependent on androgen receptor (AR) activity. Here, we found the histone demethylase KDM7A which demethylates histone H3K27 to be overexpressed in enzalutamide resistant castration-resistant prostate cancer cell line C4-2b, and investigated the molecular mechanism whereby androgen receptor activity is regulated by KDM7A. We engineered AR-positive LNCaP cells to… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
34
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 42 publications
(35 citation statements)
references
References 42 publications
(43 reference statements)
0
34
1
Order By: Relevance
“…The androgen‐activated transcription factor AR has been widely investigated. The AR features that contribute to the progression of prostate cancer consist of AR amplification, mutations, variants and alterations of coregulators, all of which lead to AR hyperactivity . In addition to what we described above, posttranscriptional regulation is also an efficient method for gene regulation.…”
Section: Discussionmentioning
confidence: 94%
“…The androgen‐activated transcription factor AR has been widely investigated. The AR features that contribute to the progression of prostate cancer consist of AR amplification, mutations, variants and alterations of coregulators, all of which lead to AR hyperactivity . In addition to what we described above, posttranscriptional regulation is also an efficient method for gene regulation.…”
Section: Discussionmentioning
confidence: 94%
“…circRNA: circular RNA; NOD-SCID: nonobese diabetic-severe combined immunodeficiency. therapeutic target for prostate cancer drugs 39 . In BrCa, KDM7A was defined as a tumor promoter.…”
Section: Discussionmentioning
confidence: 99%
“…Studies of the other members of the KDM7 family in cancer have thus far been more limited, and have uncovered both diseasepromoting and disease-suppressive roles. In prostate cancer, KDM7A is upregulated in expression and plays a role in AR-dependent gene expression and cell proliferation 175 . However, KDM7A expression is also induced under nutrient deprivation, and its ectopic overexpression in HeLa cells inhibits xenograft growth and angiogenesis 176 .…”
Section: Kdm7mentioning
confidence: 99%